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Abstract
Since arsenic trioxide (ATO) was ﬁrst approved as the front line therapy for acute promyelocytic leukemia (APL)
20 ﬁve years ago, its anti-cancer properties for various malignancies have been under intense investigation. However,
the clinical successes of ATO in treating hematological cancers have not been translated to solid cancers. This is due
to arsenic’s rapid clearance by the body’s immune system before reaching the tumor site. Several attempts have
henceforth been made to increase its bioavailability toward solid cancers without increasing its dosage albeit without
much success. This review summarizes the past and current utilization of ATO in the medical ﬁeld with primary focus
on the implementation of nanotechnology for ATO delivery to solid cancer cells. Different approaches that have been
employed to increase arsenic’s efﬁcacy, speciﬁcity and bioavailability to solid cancer cells were evaluated and
compared. The potential of combining different approaches or tailoring delivery vehicles to target speciﬁc types of
solid cancers according to individual cancer characteristics and arsenic chemistry was proposed and discussed.
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Introduction
Arsenic is a naturally occurring metalloid found as a
trace element in the earth’s crust [1]. Instead of being
present in its elemental forms; it exists as highly toxic
arsenates of metals like calcium, sodium and potassium
or as oxides and sulphides. Among its three inorganic
forms, ATO manifests as white arsenic and is
industrially produced as a by-product while roasting
arsenic containing ores and purifying the smoke [2].
The transformation of ATO from being the “king of
poisons” to a “broad spectrum anti-cancer drug” is one
of the most exciting stories in clinical oncology [3].
Despite being the mainstay of materiamedica since
the past 2400 years, ATO faced an escalating decline in
its use as a therapeutic agent in the twentieth century
due to an increasing awareness of its toxicity [4]. Its
resurgence transpired in the late twentieth century when
a group of Chinese physicians recognized it as the main
anti-leukemic ingredient in traditional Chinese medi-
cine and decided to evaluate its therapeutic potency in
treating patients with acute promyelocytic leukemia
(APL), a subtype of acute myeloid leukemia [5].
Clinical trials using ATO to treat APL patients as a
single agent or in combination with conventional
chemotherapy yielded highly encouraging results [5].
ATO was consequently approved by Food and Drug
Administration (FDA) as frontline therapy for APL in
2000 [6]. Similar clinical successes were subsequently
translated for other hematological malignancies, for
instance, acute myeloid leukemia, chronic myelogenous
leukemia, Hodgkins disease and multiple myeloma
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although not signiﬁcantly for the solid tumors [7]. Rapid
clearance of ATO and its products from the blood by
reticuloendothelial system (RES) limits the therapeutic
dose reaching the tumor site. Increasing ATO dosage
could not be a solution as it leads to systemic toxicities
such as long-term memory damage, liver failure, cardiac
failure and peripheral neuropathy [8].
Since then, several attempts have henceforth been
carried out to utilize arsenic’s signiﬁcant anti-cancer
properties for treating solid tumors by increasing its
bioavailability and speciﬁcity for carcinoma cells while
reducing its administered dosage [9]. These include
sensitizing the cells prior to ATO treatment, employing
it in combination therapy with other conventional
chemotherapeutic agents to explore their synergistic
actions or employing nanotechnology to increase
bioavailability of ATO while reducing its systemic
toxicity [10–13].
This review aims to summarize the advances that
have been made till date regarding therapeutic applica-
tions of ATO drug with an emphasis on the ongoing
involvement of nanotechnology in the current ATO
therapy in treating various malignancies.
Arsenic trioxide (ATO) history: rise, decline
and resurgence
ATO presents a rich history in medicinal applications
dating back to more than 2400 years [14]. It was used in
traditional Chinese medicine to treat syphilis, psoriasis
and rheumatism [2]. Other applications were also
reported with ATO being effective as an anti-spasmodic,
anti-pyretic, anti- periodic, caustic and sedative [14].
However, the awareness of its toxicity began to rise
when people realized that long-term chronic exposure to
ATO could cause hyperpigmentation of the skin,
cancers of lung, kidney, bladder and prostate along
with rare cases of neuropathy, encephalopathy, leuco-
penia and diabetes [6]. Consequently, by the turn of
twentieth century, its medicinal use started to decline
due to its acquired reputation of being a toxic substance
and a carcinogen.
ATO resurged as a therapeutic compound in 1990s
following an initial study at Harbin Medical University
where its anti-leukemic properties were identiﬁed in
treating APL [14]. A group of physicians at Shanghai
Second Medical University continued the study and
remarkable results were observed from the clinical trial
with patients of relapsed and refractory APL after very
low doses of intravenous ATO were administered [15].
It was a major breakthrough in treating APL relapsed
patients as the mortality rate with routine treatment i.e.
all-trans retinoic acid (ATRA) and anthracycline based
chemotherapy was 20-30% and bone marrow trans-
plantation was the only option [14]. The ﬁndings, which
were later successfully replicated in United States, led to
the approval of ATO (TrisenoxTM) by FDA as a frontline
drug for relapsed and refractory APL in 2000 [6].
Although some successes of ATO therapy have also
been observed in other hematological cancers, the
therapeutic dosage administered is relatively low, and
hence the commonly reported side effects are low grade
and reversible after ceasing the ATO therapy. However,
the same kind of clinical success has not been translated
for solid cancers in humans despite ongoing clinical
trials to investigate arsenic’s efﬁcacy on a variety of
solid cancers [15] (http://www.clinicaltrials.gov). This
is primarily due to the rapid clearance of ATO and its
metabolites from the blood by RES. Compromised
therapeutic dose of ATO reach the tumor site, therefore,
an increased dosage is required which might, in turn,
lead to systemic toxicities and long-term memory
damage and hormonal imbalance [8,16]. Therefore,
there is a crucial need for analyzing various possible
approaches of increasing the bioavailability of ATO
without raising its dosage.
Therapeutic strategies in using ATO alone or
ATO combined agents
Anti-cancer activity of free ATO has been tested on a
variety of solid tumor cell lines with positive experi-
mental results but limited clinical success. Zhao and
coworkers [17] administered direct intra-tumoral injec-
tions of ATO to human esophageal carcinoma xeno-
grafts in mice and investigated ATO distribution and its
efﬁcacy within the tumor. Tumour growth inhibition of
13.56, 62.37 and 76.92% was observed with adminis-
tration of 1, 5 and 10 mg of ATO respectively without
appreciable systemic side effects. These results pro-
vided encouraging evidence for potential clinical utility
of direct intra-tumoral injections of ATO as one form of
treatment for solid cancers. However, there is an
escalating need to investigate other approaches where
ATO can be delivered selectively to its site of action and
to penetrate inside the tumor without being toxic to
surrounding healthy tissue. Some of the approaches that
have been tested or proposed to use are outlined below
(Fig. 1).
Glutathione depleting agents
One of the key targets of ATO is glutathione (GSH), a
tripeptide molecule which protects the cells from
oxidative stress. It is involved in a number of bio-
reductive reactions and in the detoxiﬁcation of xeno-
biotics [11]. Glutathione titrates intracellular arsenic by
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forming a complex As(GS)3 [11]. This interaction is
exothermic and spontaneous at pH 7.4 and temperature
37°C (ΔG = -8.8 kcal/mol). The formation of this
complex is preceded by its export out of the cell via
multidrug resistance export proteins (MRP1-10) found
in cells [8]. Hence, substances which deplete glu-
tathione can sensitize the cells to ATO anti-tumor
activity by preventing its export out of the cells. To
verify the importance of modulation of glutathione
levels, in one experiment, glutathione content was
increased by treating the cells with N-acetylcysteine.
The anti-tumor activity of ATO was subsequently
observed to be suppressed [12]. This makes it evident
that simultaneously depleting intracellular glutathione
levels might be an effective strategy to intensify ATO
action.
Gartenhaus et al. [13] reported ascorbic acid to be one
such compound which depletes intracellular glutathione
levels. Ascorbic acid further auto-oxidises to release
H2O2 which might enhance pro-apoptotic effects of
arsenic. L-Buthioninesulphoximine (BSO) is another
drug which inhibits a critical step in glutathione
synthesis by inhibiting the rate limiting enzyme γ-
glutamyl cysteine synthetase along with generating
reactive oxygen species (ROS). This sensitizes the cells
to ATO treatment and was reported to enhance drug’s
efﬁcacy in inducing apoptosis on a number of cell lines
arising from cervix, bladder, prostrate, kidney, colon,
pancreas and breast cancers [18]. Further biochemical
studies indicated that this combination treatment blocks
the H2O2 scavenging system in the cells by interfering
with glutathione along with catalase and glutathione
oxidase enzymes. Therefore this combination of an
ROS producing drug and ROS removing inhibitor has
the potential to offer selective and efﬁcient anti-cancer
treatment [18].
Ionising radiation
When ATO is used in conjunction with ionising
radiation, radiation response was reported to be
intensiﬁed in tumor cells. ATO acts as a radiosensitizer
to tumor cells by increasing their susceptibility toward
apoptosis. Combined with a low-dose irradiation, the
dual treatment has been reported to hold a promise for
effective cancer therapy. Kang and Lee [9] observed
synergistic effect when human cervical cancer cells
Fig. 1 Key therapeutic strategies employed in the attempt to increase the efﬁcacy of ATO as a drug in treating solid tumors without
escalating its dosage [9,11,12,18–39].
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were treated with ATO along with ionising radiation.
The treatment caused regression in tumor growth by
increasing ROS, destabilizing mitochondrial membrane
and activating caspases in cancer cells.
Non-steroidal anti-inﬂammatory drugs (NSAID)
These drugs are known to enhance the susceptibility
of cancer cells toward various further anti-cancer
treatments such as biologic treatment, chemotherapy
and radiotherapy. One such drug sulindac has been
reported to sensitize the cells due to its apoptosis
inducing and anti-angiogenic properties [40]. It
increases the radiation sensitivity of cancer cells by
interfering with the tumor neovascularisation [40].
Sulindac also exhibits synergistic augmentation of
cytotoxicity when used alongside paclitaxel [41].
Similarly, when sulindacwas used alongside ATO on
human lung cancer NCI-H157 cell line, it enhanced the
caspase activation via generation of ROS [19]. This
synergistic action allowed much lower concentration of
ATO to be effective in carrying out its anti-cancer
properties.
Another NSAID drug, indomethacin is a known
inhibitor of cyclooxygenase-2 (COX-2), whose expres-
sion is signiﬁcantly increased in a variety of cancers
[19]. Hence, by acting as a COX-2 enzyme inhibitor,
indomethacin exerts its cytotoxic effects on tumor cells.
When it was used in combination with ATO, very low
doses of both drugs achieve signiﬁcant cytotoxicity
[42]. The synergism in their anti-cancer action was
clearly evident as either drug was not as toxic when it
was administered at the same concentration alone [42].
Encapsulation of ATO: as a single agent or
co-encapsulated with another drug
The advent of nanotechnology has already changed
the landscape of drug delivery. Improving the bioavail-
ability of poorly water soluble drugs, selectively
delivering the drug in a cell or tissue speciﬁc manner,
co-delivering two or more drugs, transporting the drug
to intracellular compartments/ site of action and
visualizing the site of delivery using imaging modalities
are just few of the promises that nanotechnology holds
for drug delivery [43] (Fig. 2). ATO, along with few
other organic arsenicals has already been encapsulated
in nanoparticles and their efﬁcacy is summarized and
evaluated in this review (Table 1).
Liposome encapsulation
Liposomes are lipid nanoparticles encapsulating a
hydrophilic interior with a hydrophobic membrane.
They are formed via self-assembly when certain
phospholipids are hydrated in water [44]. The hydro-
phobic membrane can entrap strongly lipophilic drugs
whereas the hydrophilic interiors can encapsulate water
soluble molecules like ATO. Zhao et al. [17] prepared
liposomes encapsulating ATO and intravenously
injected them to investigate their therapeutic effect on
C6 gliomas established in rat brains. Liposomal
preparation led to a 5-fold increase in arsenic concen-
tration in rat brains as compared to ATO solutions,
inducing apoptosis and inhibiting tumor angiogenesis
by interfering in the expression of vascular endothelial
growth factor (VEGF) with fewer side effects [17].
Fig. 2 Implementation of nanotechnology for ATO drug delivery. Amphiphilic phospholipids and block co-polymers self-assemble to
form liposomes and polymersomes respectively which can effectively encapsulate ATO in their cores. Polyethylene glycol (PEG) layer
acts as a brush to endow stealth, prevent immune recognition and recognition by serum proteins and increases their circulation half-life
in vivo. Targeting ligands such as antibodies, peptides, proteins and other small molecules attached to the membrane bilayer or PEG
facilitate the receptor-mediated endocytosis. Fluorophores attached promote the imaging of the nanoparticles and their fate in vivo.
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However, the liposomes formulated were stable for a
maximum of three days, which limited their therapeutic
use.
Nanobins
ATO forms arsenous acid, As (OH)3 when dissolved
in water at physiologic pH [8]. The latter is able to
rapidly cross the lipid membranes; thereby the lipo-
somes formulated with ATO encapsulated are highly
unstable with a stability life span of around 3 days. The
issue of such “leaky liposomes” was solved when Chen
et al. [26] developed a novel method to stably
encapsulate ATO in liposomes utilizing a metal-ion
gradient loading mechanism. Arsenic complexes with
transition metal ions such as NiII, CoII, PtII and forms a
precipitate. Utilizing this property, liposomes formed
are ﬁrst loaded with acetate solution of a transition metal
ion, followed by loading of ATO to the liposomes
formulated [22]. Efﬂux of protonated acetic acid drives
the ATO to get efﬁciently encapsulated within the
liposomes where it stably precipitates with the transition
metal ion in the form of a solid, crystalline substance
[8].
Loading of ATO via this mechanism was found to be
very efﬁcient and the lipid layer surrounding the drug
attenuates its toxicity around 4 times compared with the
free drug. These liposomes exhibit a pH dependency by
releasing the arsenic payload on encountering lower pH
in either acidic tumor milieu or the endosomes after
being taken up by the cells. Ahnet al. [21] tested the
efﬁcacy of these nanobins for orthotopic model of triple
negative breast cancer. Avisible shrinkage of tumor was
observed in rats which were subjected to the nanobin
treatment. This could be attributed to the prolonged
pharmacokinetics due to enhanced drug exposure to the
tumor caused by better penetration of liposomes along
with a reduced clearance of encapsulated arsenic within
PEGylated liposomes. The shelf life of nanobins was
greater than 6 months, probably due to the stability
provided by direct arsenic-metal bond [8].
Most recently in our laboratories, Wang and collea-
gues [24] have also established that treatment with
liposomal ATO is distinctively effective for HPV
infected cervical cancer cells, by reducing the expres-
sion of HPV-18 E6 oncogene and inducing apoptosis
more effectively than free ATO.
When acetate solution of aqua-cisplatin was
employed for arsenic complexation, the liposomes
formed had both arsenic and platinum species seques-
tered inside. Cisplatin (cis-diamine dichloroplatinumII)
is widely used to treat a variety of solid tumors such as
bladder, ovarian, testicular carcinomas [44]. On being
intracellularly hydrolysed, it yields aqua cisplatin,
which induces apoptotic cell death in cancer cells by
creating intra and inter-DNA strands cross-links [34].
This method hence provides an efﬁcient co-encapsula-
tion strategy to load both ATO and platinum drugs
within the liposomal aqueous core. To further improve
anti-cancer activity of the resulting nanobin, Chen et al.
[26] conducted a study using folic acid as a targeting
ligand to introduce ATO into malignant epithelial cancer
cell lines which overexpressed folic acid receptors (FR).
The efﬁcacy of such “targeted” liposomes was analyzed
on FR positive KB (human nasopharyngeal) cell line
and cellular uptake of ATO via FR mediated endocy-
tosis was observed to be much more than FR negative
MCF-7 (breast cancer) cell line. Moreover, the targeted
liposomal uptake was 3-6 times higher than the
untargeted ATO liposomes [26].
The targeting via nano-carriers opens a new horizon
for selectively delivering the drug to speciﬁc cancer
cells. Zhang et al. [23] utilized the overexpression of
urokinase system in ovarian epithelial cells and
consequently conjugated urokinase plasminogen acti-
vator (uPA) antibodies to nanobins. The resulting
targeted liposomes were reported to exhibit more than
4-fold increase in their uptake by the ovarian cancer
cells than their non-targeted counterparts. They also
inhibited tumor cell growth both in vitro and in vivo and
induced apoptosis along with downregulating stem cell
marker expression. Hence, utilizing the speciﬁc cancer
cell surface characteristics and identifying suitable
ligands to be attached to ATO encapsulating liposomes
are essential in enhancing the efﬁcacy of ATO therapy.
Thermosensitive liposomes
Mild hyperthermia has frequently been employed as a
stimulus to release the drug encapsulated either in the
aqueous core or in the lipid bilayer of the liposome [45].
Local mild heating can be applied directly within a
narrow temperature range. Moreover, it renders the cells
susceptible toward oxidative stress caused by ATO
treatment. Needham et al. [46] observed that inclusion
of small fraction of lysolipids in double tail lipid
liposomes causes the drug to be released quickly at
phase transition temperature Tm. Winter et al. [25]
described a liposomal formulation for encapsulation of
ATO which efﬁciently released the drug on being heated
from 27°C to 35°C. This was achieved by incorporating
lysolipid such as monopalmitoylphosphotidylcholine
(MPPC) in liposomes composed of dipalmitoylpho-
sphotidylcholine (DPPC). 10 mol% of MPPC enabled a
very rapid release of encapsulated arsenic within the
ﬁrst hour of temperature change. The ATO loading was
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accomplished using the same principle as described in
the nanobin above.
Arsonoliposomes
Arsonoliposomes are nanosized liposomes consti-
tuted from arsonolipids, which are analogs of phospho-
nolipids where arsenic replaces the phosphorus in the
lipid polar head group [47]. This type of nanoparticles is
designed to combine the anti-cancer properties of
arsenic with the enhanced efﬁcacy and reduced toxicity
of liposomes. Arsonolipids, when employed on their
own, do not possess anti-cancer activity adequate
enough to be of therapeutic value [48]. However, on
being incorporated in liposomes, they demonstrate
increased toxicity to cancer cells while being less
toxic to normal cells. Phosphotidyl choline (PC)-based
arsonoliposomes suffered from rapid clearance from
blood circulation after in vivo administration, along
with their aggregating and fusing into larger particles.
However, the PEGylation of arsonoliposomes was able
to enhance their bioavailability and pharmacokinetic
proﬁle and was shown to be effective against brain
glioma, pituitary and leukemia cell lines [27].
Polymersome encapsulation
Polymersomes are nanoparticles constituted of block
copolymers that are organized in a bilayer, similar to
liposomes, with the hydrophobic polymer wall sur-
rounding an aqueous core [44]. PEGylated PLGA
nanoparticles were synthesized as drug delivery vehi-
cles for ATO. Loading the nanoparticles with ATO was
achieved by slightly modiﬁed spontaneous emulsiﬁca-
tion solvent diffusion (SESD) method after transform-
ing the amorphous ATO into cubic crystal form and
thereby, increasing its solubility in organic solvents
[28].
Qian et al. [29] synthesized PEG-PDLLA vesicles
from amphiphilic diblock copolymer poly (D, L-lactide)
and encapsulated arsenite ion in the nanoparticles’ core.
To further improve the speciﬁcity, they conjugated an
antibody fragment, i.e. anti-CD44v6 single chain
variable fragment onto the vesicles which demonstrated
high speciﬁcity and afﬁnity toward membrane antigen
CD44v6 overexpressed on a number of epithelium
derived cancer cells. The formulated nanoparticles were
then tested against human pancreatic cancer cell line
PANC-1 and were found to be very efﬁcient in
delivering the payload within the tumor site in
comparison to the non-targeted ones.
A polymeric micelle system was developed recently
by Zhang et al. [30] utilizing a biodegradable block
copolymer. Free thiol groups on the hydrophobic block
of the polymer backbone were used to conjugate an
even more toxic form of trivalent arsenic species
compared to ATO, i.e. phenylarsine oxide (PAO). 65%
of free thiol groups were reported to conjugate with
PAO whose release from the formulated nanoparticles
was triggered by the presence of glutathione, which
perhaps acted as a competing agent for thiol group. PAO
encapsulation further served to improve micellar
stability and prevented micellar dissociation in water
or in the presence of detergents like SDS [17].
In addition to the above, a polymeric shell was also
employed in caging ATO encapsulating liposome
“nanobin” as described previously. The pH responsive
polymeric network surrounding the nano-sized lipo-
some allowed the simultaneous release of membrane
permeable trivalent arsenic ions along with membrane
impermeable Ni cations to which they form a complex.
When the pH is reduced to the levels found in late
endosomes or tumor acidic milieu, both ions were
released simultaneously, unlike nanobins, where nickel
ions remained inside the liposome while the arsenic
diffused out [49]. This is an attractive strategy because
nickel ions have been known to deplete intracellular
glutathione and ascorbate levels, thereby rendering the
cells even more susceptible toward ATO toxicity [26].
The cytotoxicity of these polymer caged nanobins was
tested against HeLa cells and they were found to be
more potent in inducing apoptosis than the plain
liposomes. The triggered release from pH change was
due to the collapse of the cross-linked polymeric
network which creates pressure points, hence pressing
liposomes and consequently destabilizing their lipid
bilayer membrane, making them release their payload
[49].
Nanoparticle mediated siRNA and arsenic
co-therapy
Zeng et al. [36] demonstrated the potential synergistic
effect of silencing mutant KRAS gene and arsenic
therapy on pancreatic tumor cell lines with excellent
results. Mutant KRAS gene plays an important role in
cell transformation and cancer development and is
known to be activated in a number of pancreatic
cancers. Therefore, downregulating it with si-RNA gene
therapy becomes an attractive treatment which gave
positive results such as inhibition of proliferative,
migratory and invasive pancreatic tumor cells [50].
When co-treated with ATO, the apoptotic effect of the
latter was substantially improved. Arsenic was encap-
sulated in poly(ethylene glycol)-block-poly(DL-lactide)
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vesicles and siRNA-complexed polyplexes were
formed from poly(ethylene glycol)-block-poly(L-
lysine) polymer. Both of the polymer nanoparticles
were simultaneously administered to the human pan-
creatic cancer cell lines PANC-1 and BXPC-3 and their
cytotoxicity was analyzed and substantiated [50].
Other nanoparticles
ATO Magnetic Nanoparticles
Encapsulating magnetic nanoparticles along with an
anti-cancer drug has many advantages. These nanopar-
ticles enable targeting under the inﬂuence of magnetic
ﬁeld and improve drug’s pharmacokinetics proﬁle in
vivo. In addition, these ferromagnetic nanoparticles can
also be utilized for inducing hyperthermia in the tumor
tissue. Magnetic ﬂuid (ﬂuid comprised of superpar-
amagnetic nanoparticles) absorbs much higher energy
than usual materials and transfers all of it to the tumor
tissue where temperature may rise to 45°C. This
concept, magnetic ﬂuid hyperthermia (MFH), where
magnetic nanoparticles are heated by applying alternat-
ing magnetic ﬁeld is gradually becoming an attractive
anti-cancer treatment [33]. By behaving as localized
points of heat, they may prevent the damage to healthy
tissues as is commonly induced in conventional
hyperthermia treatment.
In a previous study, Fe3O4 magnetic nanoparticles
were synthesized with ATO utilizing co-precipitation
and impregnation techniques to form nanosized As2O3-
Fe3O4 complexes. These nanoparticles were directly
injected into the xenograft cancer tissue of human
cervical cancer HeLa cells in nude mice and were found
to be internalised by the cancer cells. When combined
with MFH, these particles attained a steady rise in
temperature ranging from 42° to 65°C which success-
fully ablated the tissue [37]. In another study, As2O3-
MgFe2O4nanoparticles were synthesized via solvent
displacement methods and characterized [51].
When such a drug- magnetic nanoparticle complex
was co-encapsulated in a thermosensitive liposome, the
heat from these magnetic nanoparticles could lead to
destabilizing of the liposomal membrane, and the drug
could then be released at the speciﬁed location. Li et al.
[33] successfully used magnetic hyperthermia and
thermosensitive liposomes in conjunction by co-encap-
sulating Mn-Zn ferrite magnetic nanoparticles with
ATO in liposomes. Upon exposure to alternating
magnetic ﬁeld, the Mn-Zn ferrite nanoparticles served
as the heating source, causing the lipids in liposomal
membrane to reach their transition temperatures and
thereby release ATO. Their efﬁcacy was tested against
the human breast cancer MDA-MB 231 cell line and a
signiﬁcant inhibition of the cancer cells growth was
observed [33].
Song et al. [52] prepared magnetic core-polymer shell
drug delivery system encapsulating ATO. The magnetic
core employed was a small magnetic nanoparticle like
Fe3O4and the shell was composed of a biocompatible
and biodegradable polymer. This ATO drug delivering
system has been utilizing double emulsion-solvent
evaporation technique by coating the magnetite with
the polymer poly lactic acid (PLA). These hybrid
nanoparticles had high encapsulation efﬁciency and
were effective in achieving anti-cancer response along
with magnetic targeting.
ATO Albumin Microspheres
Bovine serum albumin microspheres containing ATO
were prepared employing chemical crosslink and
solidiﬁcation method [53]. The drug loading experi-
ments exhibited 29% encapsulation efﬁciency and the
release experiments in vitro suggested a slower release
of ATO after an initial burst from the microspheres, with
a cumulative percentage release close to 95% [54].
When conjugated with cell penetrating peptides, the
microspheres could display an increased cellular uptake
and consequent intracellular delivery of ATO into the
cells. For this purpose, trans-activating transcriptional
activator (Tat) peptide was employed and covalently
linked to the albumin microspheres for successful
delivering ATO into the bladder cells [55].
ATO loaded Silica Nanoparticles
Magnetite doped mesoporous silica nanoparticles
(MSN) were recently fabricated where both the internal
porous surface and external surface could be utilized for
loading different carcinogenic drugs. Moreover, they
possessed further attractive features including a large
surface area, ease of surface functionalization, biocom-
patibility and stimuli responsive drug release. Muham-
mad et al. [34] loaded camptothecin, a poorly
hydrophobic drug, into the pores while conjugating
ATO onto the surfaces of the designed silica nanopar-
ticles utilizing the interaction between arsenic and
sulphydryl groups. Besides, superparamagnetic magne-
tite nanocrystals tethered onto their surface served two
important purposes. They allowed the nanoparticles to
deliver drug payload to the site of action and also
enabled monitoring of therapeutic response via mag-
netic resonance imaging (MRI). This dual drug nano-
formulation exhibited synergism with very low con-
centrations of nanoparticles showing cytotoxic effect to
cancer cells.
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Arsenoplatins
Arsenoplatins are small molecule complexes of
aqueous form of ATO linked chemically to Pt(II).
They are formed when cisplatin, an inorganic drug, is
heated with ATO in an acetonitrile mixture for three
days [34]. The rationale behind their synthesis is that
cisplatin, cis-diamminedichloroplatinum(II), widely
used to treat ovarian, head, neck, bladder and testicular
cancers, shows synergistic activity when used alongside
with ATO. Both of them induce apoptosis in cancer cells
albeit with different mechanisms, cisplatin by causing
inter and intra-DNA crosslinking and arsenic by the
mechanisms listed above. Miodragović et al. [34]
reported the formation of arsenoplatins, which are
stable in solution, display superior anti-cancer activity
and also overcome drug resistance which is a major
limitation of platinum drugs. The As-Pt core is suitable
for ligand substitution reactions and its efﬁcacy has
been demonstrated for a variety of cisplatin-resistant
cancer cell lines, such as cisplatin resistant ovarian,
colon and glioblastoma cancer cell lines.
Others
Wimmer et al. [31] developed a glycol lipid arsenical
and reported its anti-proliferative effects on breast
cancer cells MCF-7.This compound was formed by
chemically attaching lipoamino acid to sugar. The
former increased the lipophilicity of the compound and
augmented arsenic’s toxic effects. In addition, realgar
(As4S4) quantum dots have been produced recently both
as a colloidal dispersion and as a hydrogel; the latter is
pH responsive and both forms have been reported to
possess superior anti-tumor properties [8]. Most
recently, chitosan, a well-known surface modiﬁer, was
reported to be used for coating ATO nanoparticles. The
resulting nanoparticles were biocompatible and had an
improved stability and toxicity proﬁle against prostate
cancer [38]. Additionally, these nanoparticles induced
cell cycle arrest by p21 WAF/CIP1 expression via
epigenetic remodelling in androgen dependent and
independent cell lines [56].
Conclusion
Despite an increasing awareness of toxicity arising
from arsenic compounds, ATO has established itself as
an effective, broad spectrum anti-cancer drug. Follow-
ing its successful establishment as the front line
treatment for APL patients, researchers and clinicians
have been working toward improving its effectiveness
in treatment and reducing its side effects for solid
cancers. Its poor bioavailability due to rapid clearance
from blood by RES limits the therapeutic dose of
arsenic reaching the tumor site. Therefore, using
nanotechnology to facilitate ATO delivery into solid
tumors becomes the focus in this ﬁeld. Up to date,
immense progress has been made in delivering ATO
compounds speciﬁcally to the cancer cells. ATO along
with other arsenic compounds has successfully been
encapsulated in liposomes, polymersomes and other
nanoparticles. In addition, ligands unique to the
receptors overexpressed on speciﬁc cancer cells have
been conjugated to these nanoparticles. Hence, it is
promising that delivering ATO using nanotechnology
would be employed as an anti-cancer drug option in
treating a variety of solid cancers with better efﬁcacy
and much less toxicity.
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